258 related articles for article (PubMed ID: 21738044)
41. [Ovarian cancer--modern approach to its origin and histogenesis].
Nowak-Markwitz E; Spaczyński M
Ginekol Pol; 2012 Jun; 83(6):454-7. PubMed ID: 22880466
[TBL] [Abstract][Full Text] [Related]
42. EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients.
Rao ZY; Cai MY; Yang GF; He LR; Mai SJ; Hua WF; Liao YJ; Deng HX; Chen YC; Guan XY; Zeng YX; Kung HF; Xie D
Carcinogenesis; 2010 Sep; 31(9):1576-83. PubMed ID: 20668008
[TBL] [Abstract][Full Text] [Related]
43. Differential splicing of KLK5 and KLK7 in epithelial ovarian cancer produces novel variants with potential as cancer biomarkers.
Dong Y; Kaushal A; Brattsand M; Nicklin J; Clements JA
Clin Cancer Res; 2003 May; 9(5):1710-20. PubMed ID: 12738725
[TBL] [Abstract][Full Text] [Related]
44. Reduced expression of FILIP1L, a novel WNT pathway inhibitor, is associated with poor survival, progression and chemoresistance in ovarian cancer.
Kwon M; Kim JH; Rybak Y; Luna A; Choi CH; Chung JY; Hewitt SM; Adem A; Tubridy E; Lin J; Libutti SK
Oncotarget; 2016 Nov; 7(47):77052-77070. PubMed ID: 27776341
[TBL] [Abstract][Full Text] [Related]
45. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
Mayr D; Hirschmann A; Löhrs U; Diebold J
Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
[TBL] [Abstract][Full Text] [Related]
46. Hepatocyte growth factor secreted by ovarian cancer cells stimulates peritoneal implantation via the mesothelial-mesenchymal transition of the peritoneum.
Nakamura M; Ono YJ; Kanemura M; Tanaka T; Hayashi M; Terai Y; Ohmichi M
Gynecol Oncol; 2015 Nov; 139(2):345-54. PubMed ID: 26335595
[TBL] [Abstract][Full Text] [Related]
47. Diverse mechanisms of beta-catenin deregulation in ovarian endometrioid adenocarcinomas.
Wu R; Zhai Y; Fearon ER; Cho KR
Cancer Res; 2001 Nov; 61(22):8247-55. PubMed ID: 11719457
[TBL] [Abstract][Full Text] [Related]
48. Upregulation of CXC chemokine receptor 4-CXC chemokine ligand 12 axis ininvasive breast carcinoma: A potent biomarker predicting lymph node metastasis.
Dayer R; Babashah S; Jamshidi S; Sadeghizadeh M
J Cancer Res Ther; 2018; 14(2):345-350. PubMed ID: 29516917
[TBL] [Abstract][Full Text] [Related]
49. Folate receptor alpha as a tumor target in epithelial ovarian cancer.
Kalli KR; Oberg AL; Keeney GL; Christianson TJ; Low PS; Knutson KL; Hartmann LC
Gynecol Oncol; 2008 Mar; 108(3):619-26. PubMed ID: 18222534
[TBL] [Abstract][Full Text] [Related]
50. [Effects of chemokine receptor and its ligand on migration of ovarian cancer cells].
Li F; Zhu HS; Han ZQ; Chen G; Gao QL; Jia P; Zhang AL; Xi L; Xu Q; Liao GN; Wang SX; Lu YP; Ma D
Ai Zheng; 2005 Jan; 24(1):23-7. PubMed ID: 15642195
[TBL] [Abstract][Full Text] [Related]
51. The reinforcement of invasion in epithelial ovarian cancer cells by 17 beta-Estradiol is associated with up-regulation of Snail.
Ding JX; Feng YJ; Yao LQ; Yu M; Jin HY; Yin LH
Gynecol Oncol; 2006 Nov; 103(2):623-30. PubMed ID: 16806441
[TBL] [Abstract][Full Text] [Related]
52. Effect of short hairpin RNA-induced CXCR4 silence on ovarian cancer cell.
Chen HY; Wang JM; Wang HY; Zhang YX; Liu W; Pan L; Wang WH; Chen SF; Jin WG; Wang L
Biomed Pharmacother; 2012 Oct; 66(7):549-53. PubMed ID: 22902648
[TBL] [Abstract][Full Text] [Related]
53. [Expression of hSef and FGF-2 in epithelial ovarian tumor].
Feng QL; Shi HR; Qiao LJ; Zhao J
Zhonghua Zhong Liu Za Zhi; 2011 Oct; 33(10):770-4. PubMed ID: 22335910
[TBL] [Abstract][Full Text] [Related]
54. Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas.
Hendrix ND; Wu R; Kuick R; Schwartz DR; Fearon ER; Cho KR
Cancer Res; 2006 Feb; 66(3):1354-62. PubMed ID: 16452189
[TBL] [Abstract][Full Text] [Related]
55. LMX1A as a prognostic marker in ovarian mucinous cystadenocarcinoma.
Lin CK; Chao TK; Lai HC; Lee HS
Am J Clin Pathol; 2012 Jun; 137(6):971-7. PubMed ID: 22586057
[TBL] [Abstract][Full Text] [Related]
56. [Expression of RASSF1A and RASSF1C transcripts in human primary ovarian cancers].
Ma L; Zhang JH; Liu FR; Zhang X
Zhonghua Bing Li Xue Za Zhi; 2005 Mar; 34(3):150-3. PubMed ID: 15938825
[TBL] [Abstract][Full Text] [Related]
57. [Expression and clinical significance of endostatin and vascular endothelial growth factor in ovarian carcinoma].
Shi HR; Song WJ; Chen ZM; Wu QH
Ai Zheng; 2005 Sep; 24(9):1127-31. PubMed ID: 16159439
[TBL] [Abstract][Full Text] [Related]
58. Expression of gonadotropin-releasing hormone receptor in human epithelial ovarian carcinoma.
Imai A; Ohno T; Ohsuye K; Tamaya T
Ann Clin Biochem; 1994 Nov; 31 ( Pt 6)():550-5. PubMed ID: 7880073
[TBL] [Abstract][Full Text] [Related]
59. The positivity of estrogen receptor and progesterone receptor may not be associated with metastasis and recurrence in epithelial ovarian cancer.
Chen S; Dai X; Gao Y; Shen F; Ding J; Chen Q
Sci Rep; 2017 Dec; 7(1):16922. PubMed ID: 29208958
[TBL] [Abstract][Full Text] [Related]
60. MicroRNA-9 inhibits the proliferation of oral squamous cell carcinoma cells by suppressing expression of CXCR4 via the Wnt/β-catenin signaling pathway.
Yu T; Liu K; Wu Y; Fan J; Chen J; Li C; Yang Q; Wang Z
Oncogene; 2014 Oct; 33(42):5017-27. PubMed ID: 24141785
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]